As the world grapples with the ongoing pandemic, vaccines could be the ultimate weapon in the fight against SARS-Cov-2, the virus that causes COVID-19. The need is massive, and no single vaccine or company can meet the full demand alone. With its longstanding heritage in discovery, development and manufacturing, Sanofi is well positioned to help meet this new public health emergency with a large-scale supply of new vaccines.
Since the onset of the pandemic, Sanofi teams have stepped up as one to fight COVID-19 while maintaining their commitment to produce medicines and vaccines for the millions of patients around the world who rely on us.
We have two shots on the goal of developing a vaccine against COVID-19: one through a partnership with GSK, leveraging our proven influenza platform and one in collaboration with Translate Bio, leveraging the innovative mRNA technology. Teams collaborate in real time with our partners and regulators to advance science at an unprecedented pace, without cutting any corners on safety.
In December 2020, we announced with GSK our decision to further optimize our adjuvanted recombinant protein-based COVID-19 vaccine candidate and take more time to achieve high efficacy across all adults. Pending positive results from trials, regulatory submissions could now happen in the second half of 2021, hence delaying the potential availability of our vaccine to Q4 2021.
We remain confident that our vaccine candidate, using a proven platform, could make a meaningful contribution to combating the COVID-19 pandemic. We will not stop, because we believe it is at the core of our mission to do everything we can to advance science and help protect populations against this virus.
We are navigating through challenging times, and every day is a new step into the unknown for all of us. But as a company, we have never been so close to our purpose. I am humbled by the commitment of all the Sanofi teams.
Paul Hudson, CEO Sanofi
Two vaccine candidates against COVID-19
As the pandemic continues, Sanofi is at the forefront of vaccine development, while carrying on the daily business of making and delivering medicines for patients
How Sanofi COVID-19 vaccine candidates are designed
Sanofi is taking a two-pronged approach to vaccine development to help meet global public health needs during the coronavirus pandemic.
How Clinical Trials Work
When Sanofi teams seek to make a new vaccine, they look to answer one simple question: Can the vaccine do what they expect it to do? In other words, they aim to show that a new vaccine can meet the specific objectives scientists set for it when given to the people who need it most. This is the case for all new vaccines, including those for COVID-19.